C
Cour Pharmaceuticals
Developing nanoparticle technology to help reset the immune system of multiple sclerosis (MS) patients
About Cour Pharmaceuticals
Cour Pharmaceuticals is a clinical-stage biotechnology company that develops therapies to treat patients with autoimmune and inflammatory diseases. The company's approach focuses on reprogramming the immune system by using an antigen-specific method to address the underlying cause of autoimmune diseases, rather than just managing symptoms. This involves the use of proprietary nanoparticle technology to deliver antigens to the immune system in a way that induces tolerance, thereby stopping the inflammatory destruction while preserving the normal immune function.
The company has a pipeline of product candidates for various autoimmune diseases, including myasthenia gravis, type 1 diabetes, and celiac disease. Cour Pharmaceuticals' business model involves advancing its therapies through clinical trials to demonstrate safety and efficacy. The company collaborates with larger pharmaceutical companies for the development and commercialization of its therapies. For instance, Cour has a collaboration and licensing agreement with Genentech, a member of the Roche Group, for the development of a therapy for an autoimmune disease.
Cour Pharmaceuticals has successfully raised capital to fund its operations and research, including a recent $105 million Series A financing round. The company's leadership team has experience in the biotechnology and pharmaceutical industries, guiding the company through its strategic growth and clinical development milestones.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2015
- Headquarters
- Evanston, United States
- Employees
- 77
- Open positions
- 1
- Dealroom signal
- 73.7/100
- Industry
- Health
- Sub-industry
- Pharmaceutical
- Sector
- Biotech & Life Sciences, Biotechnology, Spinout, Biotech and Pharma, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES BOther financing | Jun 2026 | $50M | $200M | Sanofi · Roche Venture Fund · Lumira Ventures | ↗ |
| DEBTDebt | Jan 2024 | $0 | — | Angelini Ventures | ↗ |
Growth signals
Latest recorded traffic for Cour Pharmaceuticals is 5.2K monthly website visits, up 23.8% over the last three months. Cour Pharmaceuticals's team declined 1.3% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A4 investors entered at this stage
Alpha Wave Global
Lumira Ventures
Roche Venture Fund
Sanofi
Series B and later1 investor entered at this stage
Angelini Ventures
Other known investors1 additional known investor
Northwestern University
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Cour Pharmaceuticals on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Cour Pharmaceuticals’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.